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Introduction 
 
Cancer: a general introduction 
In 2001 cancers were the third prevalent cause of death (12.6%) in all WHO regions 
(according to the annex table 2 of the world health report 2002, http://www.who. 
int/whr/en). Only cardiovascular diseases (29.3%) and infectious & parasitic diseases 
(19.3%) were causing more deaths. 
Cell growth is a carefully regulated process that responds to specific needs of the 
body. Very occasionally, the exquisite controls that regulate cell multiplication break 
down and a cell begins to grow and divide, although the body has no need for further 
cells of its type. When the descendants of such a cell inherit the propensity to grow 
without responding to regulation, the result is a clone of cells able to expand 
indefinitely. Ultimately, a mass called a tumor may be formed by this clone of 
unwanted cells (Lodish et al., 1995). As long as these cells remain clustered together 
the tumor is said to be benign and a complete cure can usually be achieved by 
removing the mass surgically. A tumor is counted as a cancer only if it is malignant, 
meaning that its cells have the ability to invade surrounding tissue and eventually 
metastasize to distant organs (Alberts et al., 1994). The incidence and the mortality 
rate differ for each kind of cancer. For example, liver cancer is often lethal, whereas 
prostate cancer can frequently be cured (Friedmann et al., 1984). Carcinomas are by 
far the most common forms of cancer; they originate from epithelial cells, which line 
the body cavities and form the outer layer of the skin (Weinberg, 1996). 
The tumor development occurs in different stages: First a resting cell within a normal 
population undergoes a genetic mutation that increases its ability to proliferate 
(genetically altered cell). The altered cell and its descendants look normal, but they 
have grown to a cell cluster. Years later, one in a million of these cells acquires 
another mutation that further loosens controls on cell growth (hyperplasia). Dysplastic 
cells still show signs of differentiation, but the extend is incomplete, and the 
proliferating cells are seen abnormally far above the basal lamina (dysplasia). The 
carcinoma in situ cells are proliferating and apparently undifferentiated in all the 
layers that are bordered by the basal lamina (carcinoma in situ). 
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If the genetic changes allow the tumor to cross the basal lamina to invade the 
underlying tissue and shed cells into the blood or lymph fluid, the cancer is regarded 
as invasive. The renegade cells are likely to establish new tumors (metastases) 
throughout the body leading to death by disrupting vital organ function (invasive 
cancer) (Alberts et al., 1994; Weinberg, 1996).  
Hanahan and Weinberg suggest that six essential alterations in cell physiology have to 
occur for malignant growth: self-sufficiency in growth signals, insensitivity to 
growth-inhibitory signals, evasion of programmed cell death (apoptosis), limitless 
replicative potential, sustained angiogenesis, and tissue invasion and metastasis 
(Hanahan and Weinberg, 2000). All these properties reflect alterations in the cellular 
signaling pathways that in normal cells control cell proliferation, motility, and 
survival (Martin, 2003). 
• Self-sufficiency in growth signals: Normal cells require mitogenic growth signals 
before they can move from a quiescent state into an active proliferative state. 
These signals are transmitted into the cell by transmembrane receptors that bind 
distinctive classes of signaling molecules: diffusible growth factors, extracellular 
matrix components, and cell-to-cell adhesion/interaction molecules. No type of 
normal cell can proliferate in the absence of such stimulatory signals. Many of the 
oncogenes act by mimicking normal growth signaling in one way or another 
(Hanahan and Weinberg, 2000). 
• Insensitivity to growth-inhibitory signals: Within a normal tissue, multiple 
antiproliferative signals operate to maintain cellular quiescence and tissue 
homeostasis; these signals include both soluble growth inhibitors and immobilized 
inhibitors embedded in the extracellular matrix and on the surfaces of nearby 
cells. Cancer cells must evade these antiproliferative signals if they want to 
succeed. At the molecular level, many and perhaps all antiproliferative signals are 
funneled through the retinoblastoma protein and its two relatives, p107 and p130 
(Hanahan and Weinberg, 2000). 
• Evasion of programmed cell death: Apoptosis, a physiological cell death program 
that controls normal cell numbers during development and disease, is disabled in 
tumors. Altered expression or mutation of genes encoding key apoptotic proteins 
can provide cancer cells with both an intrinsic survival advantage and inherent 
resistance to chemotherapeutic drugs (Johnstone et al., 2002).  
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• Limitless replicative potential: Telomeres control the total number of replicative 
generations of cells. The initiation of senescence and crisis depends upon correct 
telomere length. In the cancerous cell, however, the telomere-based counting 
system has completely failed and therefore the excessive proliferation cannot be 
aborted anymore (Weinberg, 1996). 
• Sustained angiogenesis: Angiogenesis is a fundamental process by which new 
blood vessels are formed and is therefore essential in reproduction, development, 
and wound repair. Folkman et al. found that tumor growth and metastasis are 
angiogenesis dependent (Folkman and Shing, 1992).  
• Tissue invasion and metastasis: Whereas normal cells are anchorage dependent 
that is mediated by cell-surface molecules, cancer cells are anchorage 
independent. To metastasize successfully, cancer cells have to detach from their 
original location, invade a blood or lymphatic vessel, arrest at the distant vascular 
bed, extravasate into the target organ interstitium and parenchyma, and proliferate 
as a secondary colony. Cancer cells do invade by releasing degradative enzymes 
(metalloproteinases) that dissolve basement membranes and other extracellular 
matrices. Patterns of metastasis can be explained in part by the architecture of the 
circulatory system (Ruoslahti, 1996). 
Many growth factors and their receptors, as well as their cytoplasmic and nuclear 
downstream effectors have been identified as oncogenes or tumor suppressor genes 
(Malumbres and Barbacid, 2001).  
Proto-oncogenes regulate the cascade of events that maintains the ordered progression 
through the cell cycle, cell division, and differentiation. A mutation within a proto-
oncogene makes a stimulatory gene hyperactive. The altered gene is called oncogene 
and has a dominant effect: only one allele needs to undergo the change. The 
oncogenic effect is generated by point mutation, chromosomal rearrangement, or gene 
amplification of the proto-oncogene sequence. In general, tumor suppressor genes 
function in growth regulatory or differentiation pathways and loss of their function 
contributes directly to the altered phenotype of cancer cells (Vogelstein and Kinzler, 
1998). In contrast to proto-oncogenes, both alleles of a tumor suppressor gene need to 
have loss-of-function (inactivating) mutations in cancer cells (Fearon, 1997). DNA 
methylation of tumor suppressor gene is also a frequent mechanism of transcriptional 
silencing in cancer. 
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Signaling pathways involved in cancer (from D. Hanahan and R. A. Weinberg, Cell, Vol. 100, 57–70): 
In this scheme genes, known to be altered in cancer, are highlighted in red. 
 
 
 
 
Cancer cells present global hypomethylation of the genome and hypermethylation of 
islands of CpG dinucleotide clusters within specific DNA regions (Di Croce et al., 
2002).  
In individuals with inactivating germline mutations in a tumor suppressor allele, 
inactivation of the remaining allele often occurs in the cancer via loss of 
heterozygosity (LOH) (Fearon, 1997). 
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The functions of some proto-oncogenes and tumor suppressor genes (Vogelstein and 
Kinzler, 1998): 
function:      examples: 
proto-oncogenes:       
tyrosine-specific protein kinases (receptor)  PDGF receptor, EGF receptor 
tyrosine-specific protein kinases (non-receptor) fes, src, BCR/ABL 
serine/threonine-specific protein kinases  raf 
GTP-binding proteins     ras proteins 
growth factors      PDGF, EGF, FGF 
nuclear proteins     myc, fos, jun, ets 
tumor suppressor genes: 
transcription factor     p53 
transcriptional repressor    Rb, WT-1 
regulation of β-catenin degradation   APC 
cyclin-dependent kinase inhibitor   p16 
 
A relatively small subset of mutations (in proto-oncogenes, tumor suppressor genes, 
or DNA repair genes) is present in the germline of individuals and predisposes them 
to cancer. The vast majority of mutations that contribute to the development of cancer 
cells are somatic and only present in the neoplastic cells of the patient (Vogelstein and 
Kinzler, 1998). 
A link between DNA repair systems and carcinogenesis is suggested by the finding 
that humans with inherited genetic defects that make specific repair systems non-
functional have an enormously increased probability of developing certain cancers 
(e.g. Xeroderma pigmentosum, hereditary non-polyposis colon carcinoma) (Lodish et 
al., 1995).     
The mutation rate within a cell is affected by mutagens in the environment and/or by 
defects in the cellular DNA repair and replication machinery. A correlation between 
mutagenesis (the production of a change in the DNA sequence) and carcinogenesis 
(the generation of cancer) has been clarified for the following three classes of agents: 
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• Chemical carcinogens such as dimethylbenzanthracene (DMBA), which typically 
cause changes in the nucleotide sequence. Some of the carcinogens act directly on 
the target cell; many others take effect only after they have been changed to a 
more reactive form by metabolic processes – notably by a set of intracellular 
enzymes known as the cytochrome P-450 oxidases.  
• Ionizing radiation such as X-rays which typically cause chromosome breaks and 
translocations. 
• Viruses, which introduce foreign oncogenes into the cell. There are two ways in 
which a proto-oncogene can be converted into an oncogene upon incorporation 
into a retrovirus: the gene sequence may be altered or truncated so that it codes for 
a protein with abnormal activity, or the gene may be brought under the control of 
powerful promoters and enhancers in the viral genome that cause its product to be 
made in excess or in inappropriate circumstances. (Alberts et al., 1994). 
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 Lung Cancer 
Lung cancer is the leading cause of cancer related death for both men and women in 
the United States and the solid tumors with the most defined relationship to a known 
environmental cause (Parker et al., 1996). 90% of all patients with lung tumors 
develop their disease because of exposure to tobacco products, and in most instances 
through cigarette smoking. Fortunately only 10% of all smokers at risk develop lung 
carcinomas despite of the fact that virtually all of these individuals have a degree of 
preneoplastic changes in their bronchial epithelium. These data and the average for 
diagnosis of 60 years suggest that the development of lung cancer occurs over a 
period of 20-30 years and involves multiple changes. 
The clinical and biological aspects of this disease are complex as four major 
histological cancer types, derived from the bronchial epithelium, can be distinguished: 
• Squamous cell carcinoma 
• Adenocarcinoma 
• Large cell undifferentiated carcinoma 
• Small cell carcinoma 
Large cell undifferentiated carcinomas, squamous cell carcinomas, and 
adenocarcinomas are collectively known as non-small cell lung cancer (NSCLC). 
NSCLCs comprise approximately 75% of all lung tumors. They generally metastasize 
later than small cell lung cancers (SCLCs) and often can be cured by surgery at an 
early tumor stage. Alterations in dominantly acting oncogenes (e.g. ras, myc, and 
cyclin D) and tumor suppressor genes (e.g. p53, p16, Rb, and FHIT-1) occur in lung 
carcinogenesis (Vogelstein and Kinzler, 1998). 
The proteins encoded by normal ras genes transmit stimulatory signals from growth 
factor receptors to other proteins downstream in the signaling cascade. Proteins 
encoded by mutant ras genes, however, fire continuously, even when growth factor 
receptors are not prompting them. Hyperactive Ras proteins are found in about a 
quarter of all human tumors. Mutations in ras family genes occur frequently in lung 
cancer (K-ras and H-ras). In NSCLC, the presence of ras mutations has been reported 
to be a negative prognostic factor, especially in patients with adenocarcinomas 
(Vogelstein and Kinzler, 1998). 
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Oncogenes, such as those of the myc family, alter the activity of transcription factors 
in the nucleus. In many types of cancer, especially malignancies of the blood-forming 
tissues, Myc levels are kept constantly high even in the absence of growth factors 
(Vogelstein and Kinzler, 1998). Members of the myc family of oncogenes (c-myc, N-
myc, and L-myc) can be activated in lung cancer, usually by gene amplification 
(Little et al., 1983). 
Cyclin D is involved in traversing the G1 cell cycle checkpoint for entry into S phase, 
at least in part by inactivating the Rb tumor suppressor protein. Thus cyclin D can act 
as an oncogene. Cyclin D1 is overexpressed in most cases of NSCLC (Vogelstein and 
Kinzler, 1998). 
The tumor suppressor protein p53 monitors the health of the cell, the integrity of its 
chromosomal DNA, and the successful completion of different steps in the cell cycle 
(Weinberg, 1996). Mutation of this gene is probably the best defined tumor 
suppressor gene change in lung cancer. The loss of gene function appears to correlate 
to the very frequent LOH that occurs on chromosome 17p13.1 in all lung cancer 
types. p53 mutations are obviously one of the most common genetic changes in all 
types of human cancer, and they have been found in 50 percent of NSCLC and 90 
percent of SCLC tumors (Chiba et al., 1990). 
By blocking the activity of the cyclin-dependent kinase partners of cyclin D p16 
prevents the advance of the cell from G1 to S phase during the cell cycle (Weinberg, 
1996). Alterations in p16 occur frequently in lung cancers, as they do in most 
common forms of human cancer (Kamb et al., 1994). This gene is a strong tumor 
suppressor candidate to account for LOH and homozygous deletions, which occur at 
chromosome region 9p21 in lung and other tumor types (Cairns et al., 1994). Loss of 
p16 function also occurs frequently via transcriptional silencing associated with 
abnormal DNA methylation of the transcription start site region (Merlo et al., 1995). 
The tumor suppressor gene Rb, which plays a critical role in the cyclin D pathway for 
cell cycle control, is altered in nearly all SCLC and in many NSCLC tumors (Hensel 
et al., 1990; Xu et al., 1991). 
Altered transcription splice products for the FHIT-1 gene, located in a frequent 
region of homozygous deletion at 3p14, have recently been described as a frequent 
characteristic of lung cancers (Sozzi et al., 1996). 
 
 
 13
Hereditary aspects of lung cancer are less well understood than for other forms of 
solid tumors in humans. Unlike for breast, colon, or renal cancers, no distinct familial 
forms of the common types of lung cancer have been defined (Vogelstein and Kinzler, 
1998). There are at least three genetic syndromes (Li-Fraumeni, retinoblastoma, and 
Bloom syndrome) that predispose to other forms of cancer in which, however, lung 
cancer may also occur: 
The Li-Fraumeni syndrome (LFS) is caused by a germline mutation in the p53 
tumor suppressor gene and causes tumor formation at multiple sites. A substantial 
fraction of lung cancers in LFS appear in non-smokers and young (< 45 years) 
patients (Lavigueur and Bernstein, 1991).  
Patients harbouring an inactivating mutation in the retinoblastoma (Rb) gene on 
chromosome 13q commonly develop retinoblastoma and osteosarcoma. Primary 
relatives of bilateral retinoblastoma patients, many of whom are carriers of the 
mutation, have been reported to develop a variety of secondary cancers, including 
lung cancer, at relatively high frequency (Goodrich and Lee, 1990). 
Bloom syndrome is an exceedingly rare recessive genetic disorder that is associated 
with defects in DNA repair. Leukemias and other cancers are quite common in this 
syndrome (German, 1993).  
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MAST9/hevin: a new tumor suppressor gene?   
To identify new putative tumor suppressor genes Schraml et al. developed a magnet-
assisted subtraction technique (MAST). They were looking for genes that were 
expressed in normal lung tissue but not in the corresponding NSCLC tissue of the 
same patient (Schraml et al., 1993). Several cDNA clones were found to be absent or 
decreased in NSCLC tissue, among them genes whose products act in diverse cellular 
processes including Ca2+ dependent reactions (calmodulin-like protein), cytoskeletal 
organization (β-actin), metabolism (glutamine synthetase), homeostasis in lung (SP-
B), and cell surface interactions (RAGE) (Schraml et al., 1994). One clone, termed 
MAST9, encoded a so far unknown cDNA fragment and was therefore chosen for 
further studies. At the same time, Girard et al. isolated the identical gene from high 
endothelial venules (HEV) of human tonsils and called it hevin (Girard and Springer, 
1995). 
The MAST9/hevin protein has a hydrophobic domain at its amino terminus, which 
most likely represents a signal for secretion, followed by an extensive acidic region, 
and a SPARC-like domain at the carboxy terminus.  
 
 
 
 
Schematic drawing of the SPARCL1 protein domains: 
The protein domains are numbered according to their amino acid (aa) position. The cysteine rich follistatin-like 
domain (FS domain) and the extracellular calcium binding domain (EC domain) are marked using the 
abbreviations. Each Ca2+ represents an EF hand.  
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This SPARC-like domain exhibits high homology (62%) to the extracellular matrix 
protein SPARC (secreted protein acidic and rich in cysteine). Therefore, 
MAST9/hevin is a member of the SPARC protein family of extracellular multidomain 
glycoproteins, which includes SPARC, SC1, QR1, testican, and TSC36/FRP (Yan and 
Sage, 1999). Because of its high homology to SPARC, MAST9/hevin has been 
renamed to SPARC-like 1 (SPARCL1) (Isler et al., 2001). SPARC has only a short 
acidic N-terminal extension (72 residues), whereas SPARCL1, SC1, and QR1 have 
considerably larger acidic N-terminal domains (403-445 residues), which are more 
closely related to each other than to SPARC. Due to the high homology of human 
SPARCL1 and mouse SC1 protein, the similar gene structure, and the homologous 
intron/exon boundaries, we suggested that SPARCL1 is the species homologue 
(orthologue) of SC1 (Isler et al., 2001). 
SC1 (synaptic complex components) was found during a screen of a rat brain cDNA 
library using a mixed polyclonal antibody directed against synaptic junction 
glycoproteins (Johnston et al., 1990). 
 
SPARCL1/SC1 
Cloning, sequencing, and characterization of the full-length SPARCL1 cDNA 
revealed an open reading frame of 1’992 nucleotides  (SC1: 1’902 nucleotides) 
encoding a protein of 75 kD (SC1: 70.6 kD). By Western Blot analysis of total human 
lung homogenate SPARCL1 was detected as a protein doublet with an approximate 
molecular weight of 75/150 kD (SC1: 116/120 kD). Whereas Girard & Springer 
predicted seven (Girard and Springer, 1995), our group found six potential N-linked 
glycosylation sites within the SPARCL1 protein  (SC1: four) (Bendik et al., 1998; 
Mendis et al., 1994). The SPARC-like domain of SPARCL1 consists of a conserved 
cysteine rich follistatin-like domain (FS domain) and an extracellular Ca2+ binding 
module (EC domain) with two calcium binding EF hands  (SC1: one) (Bendik et al., 
1998; Mendis et al., 1994). The EF hand is a highly conserved helix-loop-helix Ca2+ 
binding motif found in cytosolic proteins, whose structure and function are modulated 
by Ca2+ ions (Heizmann and Hunziker, 1991; Kretsinger, 1980; Maurer et al., 1996).  
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The amino acid sequence of the SPARC-like domain of SPARCL1 shows highest 
homology to the mouse/rat matrix glycoprotein SC1 (91% identity) followed by the 
quail QR1 protein (73% identity).  
The 2.8 kb transcript of the SPARCL1 gene is expressed in many human tissues 
including brain, heart, lung, placenta, skeletal muscle, kidney, prostate, ovary, small 
intestine, colon, stomach, thyroid, spinal cord, trachea, adrenal gland, bone marrow, 
pancreas, testis, spleen, thymus, and lymph node (Bendik et al., 1998; Claeskens et 
al., 2000; Girard and Springer, 1995). 
The 3.2 kb SC1 mRNA is expressed in similar tissues as SPARCL1. Soderling et al. 
found SC1 mRNA in mouse heart, adrenal gland, and lung and at lower levels in 
kidney, eye, spleen, and testis (1997). In situ hybridization revealed that the SC1 
mRNA is expressed widely in the brain and is present in many types of neurons 
(Soderling et al., 1997). SC1 is expressed during development of the rat cerebellum, 
but also throughout postnatal development of the brain (Johnston et al., 1990). 
Therefore, Mendis et al. looked carefully at the expression of SC1 during the 
development of the rat cerebellum at both protein and mRNA level and found 
indications that SC1 was both temporally and spatially regulated during this process 
(Mendis et al., 1994). It was proposed that SC1 might participate, not only in the 
developing nervous system, but also in the functioning of the adult brain (Johnston et 
al., 1990). Soderling et al. showed by in situ hybridization that SC1 and SPARC 
transcripts were not expressed in the same regions of a particular organ or by the same 
cell type (Soderling et al., 1997).  
Interestingly, parallel to the finding that SPARCL1 is downregulated on mRNA and 
protein level in lung tumors (Bendik et al., 1998) Nelson et al. showed that SPARCL1 
is downregulated in transformed prostate epithelial cell lines and in metastatic 
prostate adenocarcinomas (Nelson et al., 1998). The SPARCL1 transcript is also 
downregulated in colorectal (Claeskens et al., 2000; Notterman et al., 2001) and 
bladder carcinomas (Dr. P. Schraml, personal communication). Claeskens et al. found 
that SPARCL1 is equally expressed in normal and tumorous kidney tissue (Claeskens 
et al., 2000), whereas Gerritsen et al. found a twofold upregulation in renal cell 
carcinomas (Gerritsen et al., 2002). The downregulation of SPARCL1 in different 
tumor tissues prompted us to propose that SPARCL1 might be a tumor suppressor 
gene. 
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By fluorescence in situ hybridization (FISH) and comparative genome hybridization 
(CGH) techniques SPARCL1 was assigned to chromosome 4q22-25 (Isler et al., 
2001), a region, which has been speculated to contain a so far unidentified tumor 
suppressor gene (Mitra et al., 1994; Rumpel et al., 1999). In the meantime, SPARCL1 
was located to chromosome 4q22.1 by the Human Genome Project (http://genome. 
ucsc.edu). Using fluorescence in situ hybridization (FISH) analysis SC1 was localized 
to band 5E4 of mouse chromosome 5 (McKinnon et al., 1996).  
The physiological function of SPARCL1 is still unknown. SPARCL1 inhibits 
adhesion of endothelial cells indicating that SPARCL1 belongs to the family of 
adhesion modulating proteins. Girard et al. claimed therefore that SPARCL1 might 
modulate HEVEC (high endothelial venules endothelial cell) adhesiveness to 
facilitate abundant lymphocyte extravasation (Girard and Springer, 1996). As 
SPARCL1 ESTs were found at high frequency in inflammatory diseased tissues in 
artery and uterus Claeskens et el. claimed that SPARCL1 might be involved in the 
inflammatory process (Claeskens et al., 2000). SPARCL1 is also overexpressed in 
intracranial aneurysms, which are the site of a strong immune/inflammatory response 
(Peters et al., 2001). Overexpression of SPARCL1 in HeLa 3S cells inhibits the 
progression from G1 to S phase or prolonged G1 phase indicating that SPARCL1 is a 
negative regulator of cell proliferation (Claeskens et al., 2000). This result 
additionally supported our hypothesis that SPARCL1 might be a tumor suppressor 
gene. 
SC1, the mouse homologue of SPARCL1, is an astrocyte marker and may play an 
important role in reactive astrocytosis subsequent to a wide variety of neural trauma, 
including neurodegenerative diseases such as Alzheimer and acute neural damage 
(McKinnon and Margolskee, 1996). By in situ hybridization it was demonstrated that 
SC1 mRNA was induced in astrocytes surrounding a wound, reaching maximal levels 
at 10 days post-lesion (Mendis et al., 1996a). Oritani et al. suggested that SC1 could 
contribute to the nurturing environment for B- lymphocyte precursors (Oritani et al., 
1997). Surprisingly, the SC1-null mice showed no obvious defects in any organs and 
were also fertile (McKinnon et al., 2000). SC1 plays an important role in the 
developing central nervous system, whereas SPARC participates in events associated 
with skeletal development (Mothe and Brown, 2001). Mothe et al. also found that 
SC1 mRNA transport was diminished at 10 and 15 hours post-hyperthermia, but 
returned to control levels by 24 hours after heat shock.  
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As heat shock on cells grown in tissue culture induces a collapse of the cytoskeletal 
network this result can be interpreted as a blocked mRNA transport due to the lack of 
the network (Mothe and Brown, 2002).  
 
 19
QR1    
The quail cDNA clone, named QR1, was isolated during a search for genes that might 
be involved in terminal mitosis or differentiation of neuroretina cells. QR1 encodes a 
676 amino acid protein whose carboxy-terminal portion showed significant similarity 
to those of the extracellular glycoproteins SC1, SPARCL1, and SPARC. QR1 has 
only one EF hand to bind calcium at the carboxy-terminal region. The presence of a 
putative signal peptide and the lack of an internal hydrophobic transmembrane 
domain suggest that the QR1 protein is secreted. 
The avian neuroretina (NR) is a part of the central nervous system and is composed of 
photoreceptors, neuronal cells, and glial cells. Transcription of QR1 takes place only 
during the late phase of retinal development and is shut off sharply at hatching 
(Guermah et al., 1991). Its expression coincides with the stage of withdrawal from the 
cell cycle and establishment of differentiation, therefore a role for QR1 gene product 
is suggested in the process of growth arrest and establishment of photoreceptor 
differentiation (Casado et al., 1996). QR1 mRNA is detected in the neuroretina, but 
not in other embryonic tissues examined, whereas SPARCL1 and SC1 are expressed 
in many different tissues. Interestingly, in vitro the levels of this mRNA are markedly 
reduced when non-dividing NR cells are induced to proliferate by the v-src oncogene 
(Guermah et al., 1991). Therefore, the expression of QR1 is regulated indirectly 
through this oncogene.  
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Aim of the thesis 
The aim of this thesis was to find out whether SPARCL1 is a tumor suppressor gene 
with mutation or deletion in its genomic region and to reveal the mechanism leading 
to its downregulation. Furthermore, we wanted to see whether SC1 mRNA is also 
downregulated in mouse lung tumors. Using a new anti-SPARCL1/SC1 antibody we 
planned to investigate the protein expression pattern in different healthy tissues as 
well as in tumorous tissues of humans and mice.  
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Abstract 
 
SPARCL1 mRNA was shown to be downregulated in NSCLC as well as in prostate, 
colon, and bladder carcinomas. Therefore, SPARCL1 was suggested to be a tumor 
suppressor gene. By microsatellite analysis, real-time quantitative PCR, and sequence 
analysis of all exons including the intron-exon junctions and a part of the putative 
promoter region, we could not find any deletion or mutation that might be responsible 
for the downregulation of SPARCL1 in NSCLC. We conclude that SPARCL1 is 
therefore not a classical tumor suppressor gene with a deletion or mutation in one 
allele and another mutation in the second allele. 
To test whether SPARCL1 could be downregulated by repression of transcription we 
performed luciferase reporter gene assays with 10 different SPARCL1 promoter 
constructs. These experiments revealed that the presence of exon 1 is able to cause a 
reduction in luciferase activity. Furthermore, we show that the inhibitory activity of 
exon 1 can be transferred to a heterologous promoter. This indicates that SPARCL1 
downregulation might be mediated (at least in part) through transacting factors that 
bind to exon 1.  
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Introduction 
 
Lung cancer is the leading cause of cancer-related death for both men and women in 
the United States and the solid tumor with the best defined relationship to a known 
environmental cause, cigarette smoking. Four major histological lung cancer types 
exist: squamous cell, adeno-, large cell undifferentiated, and small cell lung 
carcinomas. The first three types, collectively known as non-small cell lung cancers 
(NSCLCs), comprise approximately 75% of all lung tumors. NSCLCs metastasize 
later than small cell lung cancers and can be cured by surgery if detected at an early 
stage (Vogelstein and Kinzler, 1998). 
Searching for genes downregulated in human non-small cell lung carcinomas Schraml 
et al. (Schraml et al., 1994; Schraml et al., 1993) identified and sequenced a novel 
gene termed MAST9.  Independently, Girard et al. (Girard and Springer, 1995) 
isolated an identical gene from high endothelial venules (HEV) of human tonsils and 
called it hevin. The MAST9/hevin gene encodes a glycoprotein, which exhibits 62% 
identity in its carboxy terminus to the extracellular matrix protein SPARC (secreted 
protein acidic and rich in cysteine) (Bendik et al., 1998; Girard and Springer, 1995). 
Therefore, MAST9/hevin was renamed to SPARC-like 1 (SPARCL1) (Isler et al., 
2001). SPARCL1 is closely related to two other SPARC-like proteins called SC1 
(mouse and rat, 92 and 91% identity) and QR1 (quail, 73% identity) (Bendik et al., 
1998; Girard and Springer, 1995). We suggested that SC1 is the murine homologue of 
SPARCL1 as it has similar intron sizes as well as conserved intron/exon junctions 
(Isler et al., 2001).  
SPARCL1 mRNA is expressed in many human tissues including brain, heart, lung, 
placenta, skeletal muscle, kidney, prostate, ovary, small intestine, colon, stomach, 
thyroid, spinal cord, trachea, adrenal gland, bone marrow, pancreas, testis, spleen, 
thymus, and lymph node (Bendik et al., 1998; Claeskens et al., 2000; Girard and 
Springer, 1995). Parallel to our finding that SPARCL1 is downregulated in lung 
tumors Nelson et al. (Nelson et al., 1998) showed that SPARCL1 is downregulated in 
transformed prostate epithelial cell lines and in metastatic prostate adenocarcinomas. 
In addition, the SPARCL1 transcript was found to be downregulated in colorectal 
(Claeskens et al., 2000; Notterman et al., 2001) and bladder carcinomas (Dr. P. 
Schraml, personal communication) but not in kidney tumors (Claeskens et al., 2000). 
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Gerritsen et al. (Gerritsen et al., 2002) reported a twofold upregulation of SPARCL1 
in renal cell carcinomas. The downregulation of SPARCL1 in many different tumor 
types, however, prompted us to propose that SPARCL1 might be a tumor suppressor 
gene. 
 
By fluorescence in situ hybridization (FISH) and comparative genome hybridization 
(CGH) techniques SPARCL1 was assigned to chromosome 4q22-25 (Isler et al., 
2001), a region, which has been speculated to contain a so far unidentified tumor 
suppressor gene (Mitra et al., 1994; Rumpel et al., 1999).  
In this report we evaluate whether SPARCL1 gene inactivation might be caused by a 
mutational event. We performed microsatellite analysis, real-time quantitative PCR, 
and a search for mutations by sequencing of matched normal/tumor samples from 
NSCLC patients. In addition, we performed luciferase reporter gene assays in order to 
identify regulatory elements in the SPARCL1 promoter that could be responsible for 
transcriptional repression of SPARCL1.    
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Materials and Methods 
 
Extraction of genomic DNA 
Genomic DNA was extracted from lung tissue of 54 NSCLC patients (43 men, 11 
women; age 62.7±8.9 years). Normal lung and corresponding tumor tissues were snap 
frozen immediately after resection and stored in liquid nitrogen. Genomic DNA was 
extracted from lung tissue according to standard methods (Davis et al., 1986). The 
NSCLCs consisted of 29 squamous cell carcinomas (SCCs), 10 large cell carcinomas 
(LCCs), and 12 adenocarcinomas (ADCs). For two tumors the type of NSCLC was 
not defined and one tumor was a mixed form of ADC/LCC. The extraction was done 
for an earlier study, which has been approved by the ethic committee of the St. 
Claraspital (Basel, Switzerland) (Schenk et al., 2001). 
 
Microsatellite analysis 
Microsatellite analysis was performed on chromosome 4q21-24 using 7 highly 
polymorphic microsatellite markers. The PCR reactions were performed using the Hot 
Star Polymerase kit (Qiagen), fluorescent labeled forward primers (6-FAM, HEX or 
TET), and 50 ng genomic DNA. PCR products of intermediate intensity on the gel 
(∼30ng/ µl sample) were diluted 1:20 for 6-FAM or TET labeled reactions and 1:10 
for HEX labeled reactions. For each sample 1 µl of the diluted PCR reaction was 
separated with a size standard (0.5 µl Genescan-350 TAMRA size standard; Applied 
Biosystems) on the ABI Prism 310 Genetic Analyzer (Applied Biosystems) using the 
POP4 Performance Optimized Polymer (Applied Biosystems). The microsatellite 
patterns in normal and tumor tissues were determined with the GeneScan 3.1 Analysis 
software (Applied Biosystems). 
Loss of heterozygosity (LOH) was scored if the peak height ratio of both alleles in the 
tumor DNA divided by the ratio of the corresponding alleles in the normal DNA of 
the same patient was more than 1.5 or less than 0.67.  
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Real-time quantitative PCR 
Real-time quantitative PCR was performed on genomic DNA with primers and probe 
sets specific for SPARCL1 (forward primer 5’-ATT GAG CCT CAG GAG AAA 
AAA CTC T- 3’, reverse primer 5’-TCT TGT TGG TTA GAA TCT GTG AAG GA- 
3’, and FAM labeled probe 5’-AGA GAA CAC TGA TTT TTT GGC TCC TGG 
TGT TAG- 3’) and human acidic ribosomal phosphoprotein P0, also known as 36B4 
and ARP, (forward primer 5’-CTC CAA GCA GAT GCA GCA G- 3’, reverse primer 
5’-GAA GGC TGT GGT GCT GAT G- 3’, and VIC labeled probe 5’-TCC GCA 
TGT CCC TTC GCG- 3’). Primers and probes were selected using the Primer Express 
software (Applied Biosystems). The reaction mixtures (multiplex, final volume: 50 
µl) contained 100 ng genomic DNA, 300 nM of each forward and reverse primer, 100 
nM of each probe, and 1x TaqMan Universal PCR Master mix (Applied Biosystems). 
All reactions were performed in triplicates using the ABI PRISM 7700 Sequence 
Detector (Applied Biosystems). 
The Q-gene software (Muller et al., 2002) was used to calculate the relative amount of 
SPARCL1 genomic DNA in normal and tumor tissue, normalized to human acidic 
ribosomal phosphoprotein P0. Finally, the amount of SPARCL1 in the tumor was 
divided by the amount of the corresponding normal tissue (<0.75 deletion, >1.5 
amplification) and the standard error was calculated applying the Gauss equation for 
error propagation (Bevington and Robinson, 1992). Data with a standard error greater 
than 15% were excluded. 
 
Sequencing of genomic DNA 
Fragments of the SPARCL1 gene were amplified by PCR from genomic DNA. 40 ng 
of the PCR products were cycle sequenced using the BigDye Terminator ready 
reaction mix (Applied Biosystems) according to the instructions of the manufacturer. 
The samples were then analyzed on the ABI Prism 310 Genetic Analyzer (Applied 
Biosystems) using the POP6 Performance Optimized Polymer (Applied Biosystems) 
and the ABI PRISM 310 Collection software (Applied Biosystems). The same 
primers were used for the PCR reaction and for sequencing (listed in table I). 
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amplified region   primer sequences       
 
 
promoter    F: 5’-CTT GAA AAG AAA CTC CAT GCT G-3’  
    R: 5’-TAT GGG AAA CCT CCT TCT TAG-3’ 
promoter-exon1   F: 5’-CAG CAT GGA GTT TCT TTT CAA G-3’  
    R: 5’-CAG ACG AGA ATT TGG AGG TT-3’ 
exon1-intron1   F: 5’-AGG GAA ATC CAG GAA TCT GCA-3’  
    R: 5’-CAG CTT TAT CAG ATC ACG C-3’ 
intron1-exon2-intron2  F: 5’-CAA GCT CAG TAT TTG CTA AGA C-3’  
R: 5’-TCT GCA TTA AAT GTC AGG AG-3’ 
intron2-exon3-intron3  F: 5’-GAT GAC AAC AAG AGT AAC TAG C-3’  
    R: 5’-GCA GTT GAG GTG ATC ATC ATG-3’ 
intron3-exon4   F: 5’-TGT GGC TAC AGA GTG TGA GG-3’  
    R: 5’-GTT CTG CTG ACT GTT CAT-3’ 
exon4-intron4   F: 5’-AAT CCA TTG CCT ATC ACC TC-3’  
    R: 5’-GAC ACT GTG AGA GCA CAG AG-3’ 
intron4-exon5-intron5  F: 5’-ATA CTC GTG AAA GTA TGC AC-3’  
    R: 5’-CAA GCC CAA AGT GGC AGA TT-3’ 
intron5-exon6-intron6  F: 5’-TAA CTT TGT CCA TGC TTC CT-3’  
    R: 5’-TGA TAA CCT AGG TAT CTA CC-3’ 
intron6-exon7-intron7  F: 5’-GCA GAG TGT CTT CCA GTG AG-3’  
    R: 5’-GTG TTC AGA ACT ACA TCA GC-3’ 
intron7-exon8-intron8  F: 5’-ATT ATG AGG ACT TGC CAT AG-3’  
   R: 5’-CAC CAC GTC TTT CTT CCT CA-3’ 
intron8-exon9-intron9  F: 5’-TGT TAC TGT CAC TCT TCA AG-3’  
    R: 5’-AAT GGA ACT GGG AAA TGT CC-3’ 
intron9-exon10-intron10  F: 5’-TCC TTG GTG AGC CTG AGA GT-3’  
    R: 5’-TGT GGC AGG ACC TCT CTA TG-3’  
intron10  F: 5’-TAG GGA TTC TGA TTC TAG AG-3’   
R: 5’-GGA ATT CCT CAA AAC AAG AGA TTTTCA T-3’ 
 
 
Table I: List of primer pairs used for genomic SPARCL1 amplification and sequencing in 8 NSCLC patients 
Primers binding within the exons were selected according to the published cDNA sequence of 
SPARCL1/MAST9 (GenBank accession nr X86693). For primers that bind to intron sequences own 
(unpublished) sequences were considered. All intron primers were selected to bind near to the intron/exon 
junctions.  
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Coding sequences were aligned to the MAST9 and the hevin cDNA sequences 
(GenBank accession nr X86693 and X82157), whereas promoter sequences were 
aligned to the SPARCL1 promoter sequence (AF321976). 
 
Reporter gene assay 
10 different luciferase reporter gene constructs were used in this study (see figure 4). 
The SPARCL1 promoter sequences were amplified by PCR or cut out from a 
previously characterized genomic SPARCL1 clone (GenBank accession nr 
AF321976) and were subsequently cloned into the pGL3-basic vector (Promega) as 
listed in table II. 
For the exon 1-TK construct we cut out the thymidine kinase (TK) promoter from the 
pT81-luc vector (Nordeen, 1988) using the restriction enzymes XmaI/BglII and 
cloned it into the pGL3 basic vector (construct named TK) prior to cloning of the 
SPARCL1 exon 1 into this vector (construct named exon1-TK).  
HEK293-T cells were maintained in DMEM medium supplemented with 10% FCS. 
For transient transfections HEK293-T cells were seeded in 6 well plates. After 12-16 
hours they were cotransfected with 1 µg pSV-β-galactosidase control vector 
(Promega) and 1 µg luciferase reporter gene construct using the FuGENE 6 
transfection reagent (6 µl per 2 µg vector; Roche). 24 hours later the cells were 
processed for measuring luciferase and β-galactosidase activity according to Bagutti 
et al. (Bagutti et al., 2003) using a modified luciferin substrate solution (22.5 mM 
MgSO4 and 37.5 mM glycine final pH 7.8, 0.3 mM luciferin in MgSO4/glycine, and 
7.5 mM ATP pH 7.8 in water). 
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Construct insert length  SPARCL1 clone   
A  1753 bp   nt 771-2524    
B  1943 bp   nt 774-2717    
C  1389 bp   nt 1118-2507    
D  1599 bp   nt 1118-2717    
E  1040 bp   nt 1467-2507    
F  1250 bp   nt 1467-2717    
G  708 bp   nt 1816-2524   
H  919 bp   nt 1798-2717   
exon1-TK 294 bp   nt 2423-2717  
 
 
Table II: Constructs used for luciferase assay 
The sequence of the SPARCL1 clone can be accessed on the GenBank homepage (accession nr AF321976; exon 1 
nt 2405-2714). For the exon 1 construct the TK promoter from the pT81-luc vector was cloned into the pGL3-
basic vector (construct TK) before adding the exon 1. For all other constructs the original pGL3-basic vector was 
used. 
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Results 
 
Microsatellite analysis 
To determine the frequency of deletions within or nearby the SPARCL1 locus, 
microsatellite analysis was performed on genomic DNA of 54 matched normal/tumor 
NSCLC patients using 7 highly polymorphic microsatellite markers covering 
chromosome 4q21-24. Six markers contained CA dinucleotide repeats, one contained 
GATA repeats (D4S2634). A summary of the deletion mapping and the location of 
the 7 markers used in this study are shown in figure 1. LOH was observed in 34 of 54 
NSCLC specimens (63%) at least at one of the loci tested. Ten of 54 tumors (19%) 
showed allelic loss with three or more markers. However, we could not observe any 
hot spots of deletion within chromosome 4q21-24. The lowest frequency of LOH was 
7/35 informative cases (20%) at D4S2460 (65% informative) and the highest was 
13/39 informative cases (33%) at D4S1534 (72% informative). 
69% of the squamous cell carcinoma cases showed LOH in at least one of the micro-
satellite markers tested, whereas in adenocarcinoma and large cell carcinoma cases 
55% and respectively 50% showed LOH. However, we could not detect any 
correlation of number of LOHs per patient with NSCLC type, tumor stage, number of 
lymph nodes affected, age, or gender. 
 
Real-time quantitative PCR 
Since the region covered by our microsatellite markers was around 15.2 million 
basepairs long we wanted to check for deletions of the SPARCL1 gene itself. 
Therefore, the relative amount of SPARCL1 genomic DNA was determined for the 
normal and tumor tissue by real-time quantitative PCR and by using the Q-gene 
software (Muller et al., 2002). Genomic DNA of 50 NSCLC tumors was used to 
amplify a part of SPARCL1 together with a part of the reference gene human acidic 
ribosomal phosphoprotein P0, also known as 36B4 and ARP (GenBank accession nr 
M17885). 
We found that 88% of the NSCLC patients tested retained both alleles of SPARCL1 
in the tumor tissue; in 6% of the patients we found a deletion and in another 6% of the 
patients we even found an amplification (see figure 2).  
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Figure 1: Microsatellite analysis on chromosome 4q21-24 
Patterns of LOH in 54 NSCLC patients using 7 different microsatellite markers. On the left the sample number and
at the top the name of the marker is noted. As listed below the markers are placed in the predicted order. According
to the Human Genome Project (http://genome.ucsc.edu) SPARCL1 is located in-between D4S1534 and D4S2460.
The percentage of informative cases (inf) for each marker and the percentage of LOH per informative cases are
noted at the bottom. Filled boxes stand for LOH, empty boxes for heterozygosity, and shaded boxes for homo- or
hemizygosity.  
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F gure 2: Real-time quantitative PCR of SPARCL1  
Genomic abundance of SPARCL1 in 50 NSCLC patients found with an exon 4 specific probe and primer set. The
value 1, indicating equal amount of genomic DNA in normal and tumor tissue, was marked by a block arrow whereas
the vertical line is indicating deletions or amplifications in the tumor tissue. The patients have been grouped into three
groups (from left to the right: deletion of one allele in tumor tissue, retention of both alleles, amplification in tumor
tissue). 
i 
 
 
 
 
 
 
Sequence analysis 
To detect mutations that might lead to the downregulation of SPARCL1 in NSCLC 
we sequenced the SPARCL1 gene of 8 matched normal/tumor samples. All 8 tumors 
were previously shown to have a downregulation of SPARCL1 on mRNA and protein 
level (Bendik et al., 1998). The analysis included all exons, the intron/exon 
boundaries, and a part of the putative promoter region (530 nucleotides 5’ of the exon 
1 containing a putative TATA and CAAT box). 
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We could not detect any mutations that were restricted to the tumor samples. Instead 
we found 6 polymorphisms in the exons of SPARCL1 from which 3 result in an 
amino acid change (see figure 3). All polymorphisms were detected in the normal and 
the corresponding tumor tissue and only in some of the 8 NSCLC patients. For all 
except the last one we found homo- and heterozygous patients, whereas for the exon 5 
polymorphism only heterozygous patients were examined. Two polymorphisms were 
already published by our group (Bendik et al., 1998) and two by other groups 
(Claeskens et al., 2000; Girard and Springer, 1995). We also detected 8 
sequencing errors within the MAST9/SPARCL1 sequence (GenBank accession 
number X86693). 
In summary, we could conclude from microsatellite analysis, real-time quantitative 
PCR, and sequencing that SPARCL1 is not a classical tumor suppressor gene and 
therefore the SPARCL1 mRNA and protein must be downregulated in tumors by an 
alternative mechanism. 
 
Promoter analysis 
We next considered the possibility that the SPARCL1 gene is intact but its expression 
is impaired. Transcriptional repression by hypermethylation of promoter sequences is 
a mechanism often involved in inactivation of tumor suppressor genes in cancer 
(Santini et al., 2001). In preliminary experiments we tested whether forced DNA 
demethylation could restore SPARCL1 expression in vitro. Five different SPARCL1 
negative lung cancer cell lines (A549, H1299, Hotz, Calu1, and Calu6) were treated 
with the methylation inhibitor 5-deoxyazacytidine. However, none of the tested cell 
lines could (re-) express SPARCL1 suggesting that promoter hypermethylation does 
not play a role in SPARCL1 downregulation in these cell lines (data not shown). 
Since promoter hypermethylation occurs at CpG islands, we tried to map CpG islands 
within the putative SPARCL1 promoter (GenBank accession nr AF321976) using the 
CpGpromoter program (http://cgsigma.cshl.org/CpG_promoter). In agreement with 
our preliminary data we could not detect any CpG islands within this sequence, 
indicating that promoter hypermethylation is unlikely to be the cause of SPARCL1 
downregulation in NSCLC. Therefore, deregulation of transacting factors might be 
responsible for SPARCL1 downregulation in NSCLC. 
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Figure 3: Mutational analysis by sequencing 
Polymorphisms (i) and sequencing errors found in 8 NSCLC patients. All exons, part of the putative promoter, and
the intron/exon boundaries of SPARCL1 were sequenced. The nucleotide positions (nt) of the polymorphisms are
according to the MAST9 cDNA sequence (GenBank accession number X86693). Amino acid (aa) changes and the
correct sequence (seq) are listed.  
 
 
 
 
 
 
 
 
To analyze whether SPARCL1 expression can be downregulated on the level of 
transcription, we performed luciferase reporter gene assays. Aligning the 5’ flanking 
region of exons 1 of SPARCL1 and the mouse orthologue SC1 two local stretches of 
high homology were found, which were called box 1 and 2 (Isler et al., 2001). We 
assume that this upstream region of exon 1 contains the core promoter of SPARCL1 
since it contains a putative TATA and CAAT box. Eight different promoter constructs 
of varying lengths including these two boxes were constructed from a genomic 
SPARCL1 clone (GenBank accession nr AF321976). 
 
Then HEK293-T cells were cotransfected with the promoter constructs and β-
galactosidase control vector for normalization of the transfection efficiencies. As 
displayed in figure 4 this promoter region was indeed functional and led to a 
significant increase in luciferase activity by all SPARCL1 constructs. We realized that 
the inclusion of a longer stretch of exon 1 in front of the luciferase coding region lead 
to a significant reduction in promoter activity in all constructs tested. To find out 
whether this inhibitory activity can be transferred to a heterologous promoter exon 1 
was cloned 5’ of a thymidine kinase promoter (construct called exon1-TK). 
Luciferase assays with this construct in comparison to the TK vector alone revealed 
that the addition of exon 1 was able to reduce the luciferase activity driven by the 
thymidine promoter, confirming that this DNA segment confers transcriptional 
repression.  
 
 
   
 
 
 
 
 
 
Figure 4: Luciferase reporter gene assay of the SPARCL1 promoter 
Relative luciferase activity measured 24 hours after transfecting HEK293-T cells with 10 different promoter
constructs. A: The inserts of the constructs used for luciferase assay are depicted 5’ to 3’ (black box: exon 1 or
part of exon 1, striped box: thymidine kinase promoter, grey boxes: box 1+2). On the left the names of all
constructs are indicated. B:  Relative luciferase activity (normalized with β-galactosidase) in % is noted on the
X axis whereas on the Y axis the different constructs are listed. Using brackets the corresponding constructs
(with and without exon 1) are marked. In every series of measurements the mean value of construct A was set
as 100% for the first 8 constructs (A→H), whereas the mean value of construct TK was set as 100% for the
exon 1-TK construct. 
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Discussion 
 
SPARCL1 mRNA is downregulated in many epithelial tumors (Bendik et al., 1998; 
Claeskens et al., 2000; Nelson et al., 1998; Notterman et al., 2001). In addition, 
SPARCL1 can act as a negative regulator of cell proliferation when overexpressed in 
HeLa 3S cells (Claeskens et al., 2000), therefore we hypothesized that SPARCL1 
might be a novel tumor suppressor gene. Tumor suppressor genes normally regulate 
cell growth and differentiation in a negative fashion and their downregulation or 
functional inactivation in malignant cells allows survival and cell cycle progression. 
Classical tumor suppressor genes are known to be inactivated by a deletion or 
mutation in one allele and a mutation in the second allele. Therefore, we considered 
that gene inactivation of SPARCL1 in NSCLC may be a consequence of gene 
deletions and/or point mutations leading to frameshifts, premature translation stop, or 
to amino acid changes that result in a non-functional SPARCL1 protein. Mutations 
that lead to incorrect splicing of the pre-mRNA could lead to rapid degradation or 
sequence variations in the promoter might alter the transcription rate of SPARCL1. 
To test whether SPARCL1 is a tumor suppressor gene, we initiated a LOH study 
nearby the SPARCL1 locus (in the meantime assigned to chromosome 4q22.1; 
http://genome.ucsc.edu) as well as a search for mutations by direct sequencing. So far 
we could not find a hot spot region of gene deletion within chromosome 4q21-24 by 
microsatellite analysis. We also could not detect any tumor-associated mutations in 
the SPARCL1 gene (promoter and coding regions). This indicates that SPARCL1 
downregulation is not regulated in the “classical tumor suppressor way” and that the 
SPARCL1 mRNA is downregulated using different mechanisms. 
Since preliminary result exclude promoter hypermethylation as a cause of 
downregulation and since so far little is known about the transcriptional regulation of 
SPARCL1 we performed luciferase reporter gene assays with different SPARCL1 
promoter constructs (with and without exon 1). We showed that the presence of exon 
1 consistently reduced luciferase activity of all our constructs. This attenuation of 
promoter activity by exon 1 was also transferable to a heterologous thymidine kinase 
promoter. Additional supportive evidence for a regulatory role of exon 1 comes from 
studies of the quail homologue QR1. 
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Exon 1 of SPARCL1 shows sequence homology to a promoter region of QR1 and this 
conserved region in QR1 was shown to contain a regulatory element termed A box 
(Pierani et al., 1993; Pierani et al., 1995; Pouponnot et al., 1995).   
According to the Ensembl homepage (http://www.ensembl.org/Homo sapiens; 
accession nr X86693) the intron 1 of SPARCL1 is 29.5 kb long and the whole gene 
encompasses 56.0 kb. We cannot exclude that intron 1 contains further regulatory 
sequences in addition to the 5’ sequence of exon 1 and exon 1 itself. 
It is likely that SPARCL1 expression is regulated in a complex fashion perhaps 
involving several transcription factors as it has been found for SPARC (Vial et al., 
2000). To identify factors that bind to the promoter sequence of SPARCL1 it will be 
interesting to perform a yeast one-hybrid screen and to define the binding regions of 
the transcription factors using DNA footprint assays. 
In summary, we propose that SPARCL1 is downregulated in cancer by transcriptional 
repression, possibly by a factor recognizing sequences within exon 1.         
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aa  aminoacid 
ADC  adenocarcinoma 
FCS  fetal calf serum  
HEK  human embryonic kidney 
kb  kilobasepairs  
LCC  large cell carcinoma  
LOH  loss of heterozygosity  
nr  number 
nt  nucleotide 
NSCLC non-small cell lung cancer  
SCC  squamous cell carcinoma  
SPARC secreted protein acidic and rich in cysteine 
SPARCL1 SPARC-like 1 
TK  thymidine kinase 
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Section 2: Additional experiments 
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 Materials and Methods 
 
5’ End labeling 
For end labeling 20 pMol (AC)15 primer (Microsynth), 25 µCi γ32P labeled ATP 
(Amersham), 1x forward reaction buffer (Invitrogen), and 10 units T4 Polynucleotide 
kinase (Invitrogen) were mixed in an Eppendorf tube and the volume was adjusted to 
20 µl with deionized water. The tube was quickly centrifuged and afterwards 
incubated for 10 minutes at 37°C. The kinase was then heat-inactivated for 10 minutes 
at 65°C. The non-incorporated nucleotides were removed using a Sephadex G-25 
column. For this column a 1 ml syringe was placed in a 15 ml Falcon tube before a 
little bit of glass wool was packed into the syringe. Afterwards Sephadex G-25 (in TE 
pH 8.0) was loaded and the tube was centrifuged for 5 minutes at room temperature 
with 1’200 rpm (300 g). First the syringe was placed into a new 15 ml Falcon tube, 
then the probe was loaded onto the Sephadex column, and finally the tube was 
centrifuged for 5 minutes at room temperature with 1’200 rpm (300 g). The probe was 
eluted with 50 µl TE pH 8.0. After scintillation counting, 100’000 counts per ml 
hybridization buffer were mixed with 100 µl water before boiling the probe for 10 
minutes at 100°C.      
 
Southern Blot 
2.5 µg of the genomic P1 clone 24 (for construction and purification see Isler et al., 
2001), 1x H-SuRE/Cut buffer (Roche), and 3 units of XbaI or EcoRI restriction 
enzyme (Roche) were mixed and the volume was adjusted to 20 µl with deionized 
water. After over night digestion at 37°C, the digests were loaded on a 1% agarose 
gel, which was run in a CHEF-DR II pulsed field gel electrophoresis apparatus 
(BioRad; settings: 1-6 seconds switch time, 6 V/cm voltage gradient, and 11 hours run 
time). The gel was blotted onto a Hybond N+ membrane (Amersham) by capillary 
transfer with 0.4 M NaOH at room temperature over night. Then the membrane was 
autocrosslinked with 120 mJoules in a UV Stratalinker 1’800 (Stratagene) and 
prehybridized in 20 ml Church Gilbert hybridization buffer (1% BSA, 1 mM EDTA 
pH 8.0, 0.14 M NaH2PO4, 0.36 M Na2HPO4, and 7% SDS) at 68°C. 
 42
After 1 hour prehybridization the denatured end labeled probe was added and the 
hybridization was performed at 68°C over night. The membrane was washed in 2x 
SSC/0.1% SDS for 15 minutes at 68°C, followed by 10 minutes at room temperature 
in 0.1% SSC/0.1% SDS and exposure to Kodak BioMax MR films (Kodak) for 3-7 
days.       
 
Filter lift 
Hybridizing restriction fragments found by Southern Blot were subcloned into 
Bluescript KS+ vector (Stratagene). Afterwards calcium chloride treated XL-1 blue 
competent cells (Stratagene) were transformed with these constructs. The cells were 
plated on prewarmed LB plates containing 100 µg/ml ampicillin and incubated over 
night at 37°C. The next day a piece of Hybond N+ membrane was carefully placed 
onto the agar plate with the transformed cells. After 1 minute the membrane was 
removed and placed colony side up on a dry filter paper. Then the membrane was 
placed colony side up on a pad of filter paper soaked in denaturing solution (1.5 M 
NaCl, 0.5 M NaOH). After 7 minutes the membrane was placed colony side up on a 
pad of filter paper soaked in neutralizing solution (1.5 M NaCl, 0.5 M Tris pH 7.2, 
and 1 mM EDTA). After 3 minutes the membrane was once more placed colony side 
up on a pad of filter paper soaked in neutralizing solution for 3 minutes. Finally the 
membrane was washed in 2x SSC, air-dried, and autocrosslinked with 120 mJoules in 
a UV Stratalinker 1’800 (Stratagene). Then the membrane was prehybridized in 20 ml 
Church Gilbert hybridization buffer for 1 hour at 68°C. Afterwards the denatured end 
labeled probe was added and the hybridization was performed at 68°C over night. The 
membrane was washed in 2x SSC/0.1% SDS for 10 minutes at 68°C, followed by 10 
minutes at room temperature in 2% SSC/0.1% SDS and was exposed to Kodak 
BioMax MR films (Kodak) for one day. Clones, which were hybridizing with the 
probe, were picked to start a culture. After QIAprep miniprep (Qiagen) DNA 
extraction the inserts of the clones were sequenced on the ABI Prism 310 Genetic 
Analyzer (Applied Biosystems) using the BigDye Terminator ready reaction mix 
(Applied Biosystems).        
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cDNA synthesis and riboprobe production 
From 2 µg mouse brain total RNA cDNA was produced using Oligo(dT)15 primer 
(Promega) and the Omniscript reverse transcriptase (Qiagen) according to the 
instructions of the manufacturer. Afterwards a SC1 specific fragment (nt 1385-1662; 
GenBank accession nr U64827) was amplified by PCR and cloned into the 
pBluescript II SK- vector (Stratagene) using the EcoRI and an artificial SalI 
restriction site. The insert was sequenced before linearizing the plasmid with EcoRI or 
SalI. DIG-labeled riboprobes were synthesized from 1 µg of the linearized plasmid 
using the DIG RNA labeling mix (Roche) according to the instructions of the 
manufacturer and T3 (sense: SalI) or T7 (antisense: EcoRI) RNA polymerase 
(Promega). 
 
Northern Blot 
For testing the riboprobes total RNA was extracted from adult mouse brain using the 
peqGOLD RNApure reagent (Peqlab Biotechnologie; according to the instructions of 
the manufacturer) followed by a lithium chloride praecipitation. 15 µg total RNA 
from mouse brain or 3 µg RNA ladder (New England BioLabs), 1x MOPS buffer (20 
mM morpholinopropansulfonic acid, 5 mM NaAcetate, and 1 mM EDTA pH 8.0; 
final pH 7.0), 6.5% formaldehyde, 50% formamide, and 0.25 µg/µl ethidium bromide 
were mixed and the volume was adjusted with DEPC treated water to 30 µl. The 
samples were heated to 70°C for 5 minutes and cooled on ice for 5 minutes. Finally 5 
µl Blue/Orange 6x loading dye (Promega) were added. 1 g agarose was mixed with 10 
ml 10x MOPS buffer and 85 ml DEPC treated water and melted in the microwave. 
After cooling down to 60°C 5 ml 37% formaldehyde were added and the gel was 
poured. The gel was prerun 10 minutes in 1x MOPS buffer at 50 Volts, the samples 
were loaded and then the gel was run at 50 Volts for 2.5 hours. After electrophoresis 
the gel was rinsed for 10 minutes in 10x SSC before it was blotted onto a Hybond N+ 
membrane (Amersham) by capillary transfer with 10x SSC at room temperature. 4 
hours later the membrane was autocrosslinked with 120 mJoules in a UV Stratalinker 
1’800 (Stratagene), quickly rinsed in DEPC treated water, and air-dried. The 
membrane was then placed in a hybridization bottle with 10 ml hybridization buffer 
(5x SSC, 0.5% SDS, 50% deionized formamide, and 2% blocking reagent from 
Roche). 
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500 ng of the DIG labeled riboprobe were mixed with 100 µl hybridization buffer and 
heated to 80°C for 3 minutes. After 5 minutes cooling on ice the probe was added to 
the hybridization buffer and the membrane was incubated in this solution at 68°C over 
night. Then the membrane was washed quickly in 2x SSC/0.5% SDS followed by 2 
times for 15 minutes in 200 ml 2x SSC/0.5% SDS with vigorous shaking at room 
temperature. The membrane was washed twice for 15 minutes in 50 ml 0.1x 
SSC/0.5% SDS with vigorous shaking at 68°C. The membrane was transferred to a 
tray with 100 ml DIG buffer 1 (0.1 M maleic acid and 150 mM NaCl, final pH 7.5) 
and incubated for 5 minutes at room temperature with gentle shaking. Next the 
membrane was blocked for 1 hour at room temperature in 100 ml DIG buffer/1% 
blocking reagent (Roche) with gentle shaking. The membrane was then incubated 
with anti-digoxigenin-AP antibody (Roche) diluted 1:20’000 in 10 ml DIG buffer/1% 
blocking reagent (Roche) for 30 minutes at room temperature with gentle shaking. 
Afterwards the membrane was washed 3 times for 15 minutes in 200 ml DIG buffer 2 
(DIG buffer 1/0.3% Tween 20) with shaking. The membrane was equilibrated for 5 
minutes in 50 ml freshly made DIG buffer 3 (0.1 M Tris pH 9.5/0.1 M NaCl) before 
incubation for 5 minutes with 5 ml CDP star (Roche) diluted 1:100 in DIG buffer 3 at 
room temperature. Excess buffer was blotted off before exposure of the membrane to 
Kodak BioMax MR films (Kodak).             
 
In Situ Hybridization 
12 weeks old A/J mice were injected intraperitoneal with 3.5 mg NNK per 25 g of 
body weight. 12 months later the mice were sacrified and the lungs were perfused 
with paraformaldehyde before embedding in paraffin. For in situ hybridization 16 µm 
lung paraffin sections from NNK treated A/J mice were used (tissue kindly provided 
by Dr. Karin Wertz, DSM Nutritional Products, VFHC, Basel). 
A modified version of the in situ hybridization protocol from Henry et al. (Henry et 
al., 1996) was used. The sections were not additionally fixed after rehydration. After 
proteinase K digestion the slides were soaked for 10 minutes in 0.2% glycine/PBS 
solution. The prehybridization step was done at 68°C for two hours in 5x SSC, 50% 
formamide, 0.1% Tween 20. For hybridization 5x SSC, 50% formamide, 0.1% Tween 
20, 1x Denhardt’s solution, 50 µg/ml heparin, and 50 µg/ml type III baker’s yeast 
RNA was used. 
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3 µg/ml denatured riboprobe were added and the hybridization was performed at 68°C 
for 2 nights. All washing steps were done without addition of CHAPS and at 68°C 
instead of 60°C. The 1:3 prehybridization solution/2x SSPE washing step was also 
performed at 68°C.  RNAse A digestion was done for 20 minutes. The anti-
digoxigenin-AP antibody (Boehringer Mannheim) was incubated with the slides over 
night at room temperature. Afterwards they were washed 3 times in TBST for 20 
minutes before incubation in BM purple (Roche). This reaction was stopped by 
incubation in PBS/20 mM EDTA for 10 minutes before fixation for 45 minutes in 4% 
paraformaldehyde. Then the sections were embedded in DPX mountant for histology 
(Fluka).   
   
Antibody production and purification 
A rabbit antibody against a SPARCL1/SC1 peptide (DPNKDKHITLKEWGHCFG) 
was obtained from Neosystems S.A. (Strasbourg, France).  
The serum of the rabbits was purified over a CNBr-activated Sepharose 4B 
(Amersham) column coupled with peptide according to the instructions of the 
manufacturer. In brief, 0.3 g of CNBr-activated Sepharose 4B (Amersham) was 
swollen in 3 ml 1 mM HCl for 15 minutes on a shaker at room temperature (in 
general, 1 g freeze dried material gives about 3.5 ml final gel volume). Then the gel 
was washed on a sintered glass filter with 200 ml 1 mM HCl before washing with 5 
ml coupling buffer (0.1 M NaHCO3 and 0.5 mM NaCl, pH 8.3). Afterwards the gel 
was immediately transferred to the peptide solution in a 15 ml Falcon tube (5 mg 
peptide in 2 ml coupling buffer; in general, 5-10 mg protein are coupled to 1 ml of 
gel). After incubation for two hours on a shaker at room temperature the mixture was 
centrifuged for 5 minutes at 1’500 rpm (≈ 350 g). The supernatant was removed, the 
gel was gently resuspended in 10 ml blocking buffer (1 M glycine in coupling buffer) 
and incubated on a shaker at 4°C over night. To remove excess of uncoupled peptide 
the gel was washed 5 times on a sintered glass filter alternately with 50 ml coupling 
buffer and with 50 ml wash buffer (0.1 M NaAcetate pH 4.2 and 0.5 M NaCl). The 
gel was washed with coupling buffer, then with PBS and finally it was stored in 
borate buffer (50 mM Na3BO3 pH 8.0, 150 mM NaCl) at 4°C. The gel was transferred 
to a column and washed with 0.1 M glycine pH 2.5. In the meantime, the serum was 
centrifuged in 30 ml Corex tubes for 10 minutes at 9’000 rpm (≈ 6’300 g). 
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The supernatant was transferred to a 50 ml Falcon tube. After washing the column 
with PBS the serum was twice loaded onto the column. Another washing step with 
PBS was performed before the anti-SPARCL1/SC1 antibody was eluted with 0.1 M 
glycine pH 2.5. 800 µl aliquots were collected in Eppendorf tubes containing 200 µl 
Tris pH 7.5 to neutralize the samples. 
Aliquots containing antibodies were detected by SDS-PAGE (Gelcode Blue Stain 
Reagent from Pierce; according to the instructions of the manufacturer). The 
specificity of the antibody was tested by ELISA on wells coated with peptide and by 
Western Blot on transfected/untransfected HEK293-T cells. 
 
ELISA (Enzyme-Linked ImmunoSorbent Assay) 
For testing whether the antibody recognizes the peptide the wells of a 96 well plate 
were coated with 50 µl 1 mM SPARCL1/SC1 peptide (see antibody production) at 
4°C over night. Unbound peptides were removed by aspiration and the wells were 
rinsed with PBS. Blocking was then performed with 100 µl 4% skim milk/PBS for 
one hour at 37°C. After three washing steps with PBS 50 µl of the anti-SPARCL1/ 
SC1 antibody diluted differently in 1% skim milk/PBS was added to the wells. Five 
washing steps with PBS were done before 50 µl horseradish peroxidase-conjugated 
goat anti-rabbit antibody (Socochim) was added (1:1’000 in 1% skim milk/PBS) and 
incubated for 1 hour at 37°C. Five washing steps with PBS were performed and then 
100 µl OPD (1,2-phenylendiamine-dihydrochloride) solution (20 mg OPD, 24 ml 0.1 
M citric acid, 26 ml 0.2 M Na2H-phosphate, and 40 µl 30% H2O2) were added for 10 
minutes at room temperature. The reaction was stopped by addition of 50 µl 2.5 M 
H2SO4 before reading absorbance at 490 nm (and 630 nm as reference) in an ELISA 
reader.   
 
Cell extract (HEK293-T) 
HEK293-T cells were maintained in DMEM medium supplemented with 10% FCS 
and grown in a CO2-incubator at 37°C (6% CO2). For transient transfections 1.5x105 
HEK293-T cells were seeded in 6 well plates. After 24 hours the cells were 
transfected with 2 µg human SPARCL1 construct using the FuGENE 6 Transfection 
Reagent (Roche; according to the instructions of the manufacturer). 
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After incubation for 48 hours the cells were quickly rinsed with ice-cold PBS and then 
scraped with 200 µl RIPA buffer containing proteinase inhibitors (120 mM NaCl, 50 
mM Tris pH 8.0, 1% NP-40, 0.5% Deoxycholate, 0.1% SDS, and complete mini 
proteinase inhibitor; Roche, concentration according to the instructions of the 
manufacturer). The scraped cells were transferred to a 1.5 ml Eppendorf tube before 
incubation on ice for 30 minutes. The tubes were centrifuged at 12’500 rpm for 10 
minutes at 4°C in a tabletop centrifuge. The supernatant was frozen at -80°C. As 
negative control untransfected cells were used. 
To express human SPARCL1 a construct based on the pcDNA3.1/Zeo+ vector 
(Invitrogen) was produced. Using the NheI-EcoRI restriction sites, a Kozak sequence, 
an ATG start site, a human influenza A haemaglutinin signal peptide for secretion, 
and a 5x myc tag were added to the pcDNA3.1/Zeo+ vector. The human SPARCL1 
sequence lacking its signal peptide was ligated into the modified vector (3’ of the myc 
tag) using the EcoRI-ApaI restriction sites. 
 
Mouse tissue extract 
Fresh tissue (cortex, cerebellum, kidney, liver, lung, heart, and small intestine) from 
2.5 months old nude mice was frozen directly after dissection on dry ice. The frozen 
tissue was grinded with liquid nitrogen in a mortar. The pulverized tissue was 
transferred to an Eppendorf tube and 750 µl lysis buffer containing proteinase 
inhibitors (25 mM Tris pH 7.5, 50 mM KCl, 2 mM MgCl2, 1 mM EDTA, 5mM DTT, 
and complete mini proteinase inhibitor; Roche, concentration according to the 
instructions of the manufacturer) were added. The dissolved tissue was Dounce 
homogenized and then centrifuged at 5’000 rpm for 10 minutes at 4°C in a tabletop 
centrifuge. 
The concentration of the supernatant (containing soluble, non nuclear proteins) was 
determined using the Bio-Rad Protein Assay (Bio-Rad) and the mouse tissue extract 
was stored at -80°C. 
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Human tissue extract 
Fresh human tissue (colon epithelium and muscle) was frozen directly after surgery 
on dry ice. The frozen tissue was basically processed in the same way as the mouse 
tissue, however, with a different lysis buffer (120 mM NaCl, 50 mM Tris pH 8.0, 1% 
NP-40, 0.5% Deoxycholate, 0.1% SDS, and complete mini proteinase inhibitor; 
Roche, concentration according to the instructions of the manufacturer).  
 
Western Blot 
To 100 µg mouse/human tissue extract or 22.5 µl of cell extract 4x SDS-PAGE 
sample buffer (1.6x stacking gel buffer, 4% SDS, 17.4% glycerol, 20% β-mercapto-
ethanol, and 0.01% bromphenolblue) was added to a final 1x concentration. The 
samples were boiled for 5 minutes at 95°C and the denatured protein extracts were 
loaded on a 7.5% SDS-PAGE Minigel (BioRad). After gel electrophoresis proteins 
were transferred electrophoretically to Immobilion P membrane (Millipore) for two 
hours at 45 mA per gel. The membrane was washed 3 times for 5 minutes in TBST 
with vigorous shaking before blocking in 3% skim milk/TBST for one hour at room 
temperature on a shaker. Then it was transferred to a new tray with anti-
SPARCL1/SC1 antibody (final concentration 300 ng/ml) in 3% skim milk/TBST. 
After incubation over night at 4°C on a shaker the membrane was washed 3 times for 
5 minutes in TBST with vigorous shaking. The membrane was then incubated with 
horseradish peroxidase-conjugated goat anti-rabbit antibody (Socochim) in 3% skim 
milk/TBST (1:10’000) for one hour at room temperature on a shaker. After washing 3 
times for 5 minutes in TBST with vigorous shaking immunoreactive bands were 
identified by incubation for 5 minutes with ECL Western Blotting detection reagents 
(Amersham) and exposure to Kodak BioMax MR films (Kodak). As protein 
molecular weight standard Benchmark pre-stained marker or Benchmark marker 
(Invitrogen) were used.   
 
Immunofluorescence 
Cos-7 cells (african green monkey) were maintained in DMEM medium 
supplemented with 10% FCS and grown in a CO2-incubator at 37°C (6% CO2). 
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For transient transfections 1x105 Cos-7 cells were seeded in a 35 mm dish with 4 
compartments (Greiner Bio-One). After 24 hours each compartment was transfected 
with 0.25 µg human SPARCL1 construct (see cell extract) using the FuGENE 6 
Transfection Reagent (Roche; according to the instructions of the manufacturer). 
After 24 hours the cells were fixed for 15 minutes with 4% paraformaldehyde before 
they were washed 3 times for 5 minutes with 1% BSA/PBS. Then the cells were 
permeabilized for 5 minutes with 0.1% Triton X-100 in PBS and washed again 3 
times for 5 minutes with 1% BSA/PBS. After blocking in 2% BSA/PBS for one hour 
at room temperature, the anti-SPARCL1/SC1 antibody (final concentration 6 µg/ml) 
was added in 1% BSA/PBS and the cells were incubated at 4°C over night. The next 
day the cells were washed 3 times for 5 minutes with 1% BSA/PBS before adding the 
goat anti-rabbit rhodamine antibody (Santa Cruz) diluted 1:1’000 in 1% BSA/PBS for 
1 hour at room temperature. Then the cells were washed 3 times for 5 minutes with 
1% BSA/PBS and finally they were embedded in Mowiol (Calbiochem).      
 
Immunohistochemistry (mouse) 
5 µm thick paraffin sections were dried on Super Frost Plus slides (Menzel-Glaeser) 
over night at room temperature before two deparaffinization steps of 10 minutes in 
xylene were performed. Afterwards the sections were rehydrated by incubating 5 
minutes in 100, 80, 70% ethanol, and finally PBS. To quench the endogenous 
peroxidase activity the slides were soaked for 30 minutes in 3% H2O2/ 10% methanol 
followed by 5 minutes washing in PBS. Blocking was performed in 10% normal goat 
serum/0.3% Triton X-100 in TBS/4 drops Avidin D per ml (Blocking kit; Vector 
Laboratories) for 30 minutes at room temperature. The sections were rinsed for 5 
minutes in TBS, then the anti-SPARCL1/SC1 antibody (final concentration 10 µg/ml) 
was added in 10% normal goat serum/0.3% Triton X-100 in TBS/4 drops Biotin per 
ml (Blocking kit; Vector Laboratories). After incubation at 4°C over night the slides 
were washed 3 times for 5 minutes with TBS. Then the sections were incubated with a 
biotinylated goat anti-rabbit antibody (Vectastain ABC kit; Vector laboratories) 
diluted 1:200 in 10% normal goat serum/0.3% Triton X-100 in TBS for 30 minutes at 
room temperature. 
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After washing 3 times for 5 minutes with TBS the sections were incubated for 30 
minutes with ABC reagent (prepared 30 minutes before use: 1 drop reagent A in 2.5 
ml TBS and 1 drop reagent B; Vectastain ABC kit; Vector laboratories). The slides 
were soaked another 5 minutes in TBS and then they were incubated for 20 minutes in 
50 mM Tris pH 7.6 at room temperature. Afterwards DAB substrate (DAB substrate 
kit for peroxidase: 2.5 ml ddH2O, 1 drop buffer stock solution, 2 drops DAB stock 
solution, and 1 drop hydrogen peroxide solution; Vector Laboratories) was added to 
the sections. After 10 minutes incubation the slides were rinsed for 5 minutes in tap 
water and then they were counterstained for 10 seconds in Mayer’s haematoxylin 
solution (Sigma diagnostics). The slides were dehydrated and after incubation in 
xylene embedded in DPX mountant for histology (Fluka). 
 
Immunohistochemistry (human) 
Immunohistochemistry on 5 µm thick human colon paraffin sections was performed 
according to the instructions of the Discovery system (Ventana). The anti-SPARCL1/ 
SC1 antibody was used at a final concentration of 12 µg/ml. 
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Results 
 
Search for CA repeats close to the SPARCL1 gene  
Unfortunately, we did not find any hot spot of deletion by microsatellite analysis 
using 7 different highly polymorphic microsatellite markers (see section 1 of this 
thesis). At the time the study was performed, we only had a rough chromosomal 
localization of SPARCL1 (4q22-25) from FISH and CGH (Isler et al., 2001) and the 
region encompassed by our microsatellite markers was about 15.2 million basepairs 
long. Therefore, we wanted to know if some so far unidentified CA repeats could be 
detected near by the genomic region of SPARCL1 and if these potential CA repeats 
could be used for further microsatellite analysis experiments. By Southern Blot 
analysis we were looking for CA repeats on the genomic P1 clone 24 (91.6 kb 
encompassing the 5’ promoter region and exon 1 to intron 6 of human SPARCL1 
gene; for construction and purification see Isler et al., 2001). With an end labeled 
(AC)15 primer we detected several bands in the EcoRI or XbaI digests of the P1 clone 
24 and these bands were subcloned in Bluescript KS+ vector. After filter lift assay 
and hybridization of the subcloned fragments with the end labeled (AC)15 primer all 
colonies with CA repeats were used to start bacteria cultures. The inserts of the clones 
were sequenced to find the CA repeats. Unfortunately, the longest stretch found (at 
the 3’ end of the intron 1) was only 4 CA repeats long and was therefore much too 
short for microsatellite analysis. 
 
Validation of riboprobes: Northern Blot analysis and in situ 
hybridization on mouse brain sections 
SC1 specific riboprobes were tested for specificity using Northern Blot analysis. Total 
RNA from mouse brain was separated on a gel and transferred electrophoretically to 
Hybond N+ membrane. After hybridization we detected a single band in brain with 
the antisense probe, whereas the sense probe did not detect any band (see figure 1). 
The size of the band corresponds to the published mRNA size of SC1 (3.2 kb). 
Additionally this band seems to be specific as it is not detected with the sense probe.  
 
 
 52
By in situ hybridization the riboprobes were also tested on 10 µm adult mouse brain 
paraffin sections. The staining found (dentate gyrus, pyramidal cells) was in 
agreement with published data (Mendis et al., 1996b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Northern Blot analysis with mouse brain RNA 
To test the specificity of the SC1 riboprobes used for in situ hybridization we performed Northern Blot analysis 
with mouse brain RNA. On the left the antisense, on the right the sense probe was used for hybridization. 
 
 
In situ hybridization on lung sections of A/J mice 
To find out whether SC1 is also downregulated in mouse lung tumors, in situ 
hybridization was performed on lung paraffin sections of A/J mice (tissue kindly 
provided by Dr. Karin Wertz, DSM Nutritional Products, VFHC, Basel). This study 
included three A/J mice, which were treated with the tobacco specific nitrosamine 
NNK (=4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) to enhance the induction of 
lung tumors. The resulting lesions have a similar histology as human lung adenomas 
and evolve over a distinct progression from hyperplasia, to benign appearing 
adenomas, and then to frank carcinomas. By in situ hybridization we could show that 
SC1 is also downregulated in mouse lung tumors as it is seen in human lung cancers 
(see figure 2). Only two of the three mice developed lung tumors, but all tumors 
lacked SC1 mRNA. This result suggests that the downregulation of SPARCL1/SC1 
might be important for lung tumor formation.  
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Figure 2: In situ Hybridization of mouse lung sections 
SC1 mRNA expression and downregulation found with an exon 4-6 specific riboprobe in lung of A/J mice treated 
with NNK. On the left H+E staining is shown whereas on the right in situ hybridization is shown (bar 100 µm).  
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Production of a polyclonal antibody and validation 
SPARCL1 mRNA expression is downregulated in many human tumors as well as in 
murine lung tumors. Therefore, we were interested in the precise localization of the 
SPARCL1/SC1 protein in normal and neoplastic tissue sections. 
An existing polyclonal chicken antibody against the acidic N-terminal part of the 
SPARCL1/MAST9 protein (anti-human MAST9∆; (Bendik et al., 1998)) proved to 
work very specifically on Western Blots. However, we were not able to establish 
immunohistochemistry using this antibody, neither on paraffin sections nor on 
cryosections. Therefore, we decided to raise new antibodies against a different part of 
the SPARCL1 protein. We selected a C-terminal peptide that exhibited 100% identity 
between the human and mouse SPARCL1 sequence. To avoid cross-reactivity we 
took care to have minimal homology between SPARCL1 and the closely related 
SPARC protein (see figure 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Alignment of SPARCL1/SC1 peptide with mouse and human SPARC  
For antibody production a peptide from the C-terminal end of SPARCL1 was chosen which is 100%
identical to the mouse SC1 sequence. The SPARCL1/SC1 peptide is aligned to the corresponding sequence
of SPARC (mouse: GenBank accession nr AAH04638, human: GenBank accession nr AAH08011).  
 
 
The peptide was coupled to ovalbumin and two rabbits were immunized. As the final 
bleedings showed relative high background in Western Blots, we decided to affinity 
purify the antibodies over a Sepharose column with coupled peptide. The purified 
antibody was tested for specificity by ELISA and by Western Blot analysis.  
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  Using ELISA on wells coated with uncoupled peptide we could show that the new 
anti-SPARCL1/SC1 antibody is recognizing the peptide. To test the specificity of the 
purified anti-SPARCL1/SC1 antibody on Western Blots we used RIPA extracts from 
HEK293-T cells that were transiently transfected to express the human SPARCL1 
protein. As negative control non-transfected HEK293-T cells were used. 
As expected, we detected two bands of 70/150 kD in SPARCL1 expressing cells (see 
figure 4A), which might represent mono- and dimers of the SPARCL1 protein 
(Bendik et al., 1998). Surprisingly, the 70 kD band was also present in non-
transfected cell lysates. Preincubation of the anti-SPARCL1/SC1 antibody with the 
SPARCL1/SC1 specific peptide blocked the 150 kD band but not the 70 kD band 
(4B). The unspecific band could be blocked by changing the blocking and antibody 
dilution solutions from 3% skim milk to 10% goat serum (4C). In subsequent 
immunohistochemical experiments all blocking and antibody dilution steps were 
performed using 10% goat serum. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Western Blot analysis with HEK 293-T cell extracts 
To test the specificity of the new anti-SPARCL1/SC1 antibody Western Blot analysis with transfected (+) and
untransfected (-) HEK 293-T cells was performed. For transfection a human SPARCL1 construct was used. 
A: standard Western Blot procedure using 3% skim milk for blocking and antibody dilutions. B: the antibody
was preincubated with the corresponding peptide. C: blocking was performed with 10% goat serum instead of
3% skim milk. 
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 Immunofluorescence on Cos-7 cells transfected with the human SPARCL1 construct 
showed a nice Golgi/ER staining (see figure 5) as expected from the fact that this 
construct contains a signal peptide for secretion.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Immunofluorescence of SPARCL1 transfected Cos-7 cells 
Cos-7 cells were transfected with a human SPARCL1 construct and immunofluorescence was performed with the 
anti-SPARCL1/SC1 antibody. The Golgi/ER staining showed here was not obtained when the cells were not 
transfected or when the antibody was preincubated with the corresponding peptide. 
 
 
 
 
SC1 expression in murine tissue 
To find out more about the SC1 protein expression in mouse we conducted Western 
Blot analysis with extracts from different mouse tissues (cortex, cerebellum, kidney, 
liver, lung, heart, and small intestine). We detected a single band of about 70 kD in all 
tissue extracts which corresponded to the predicted molecular weight of SC1 
monomers but no bands that could correspond to SC1 dimers (see figure 6). The 70 
kD band was specific as it could be blocked by preincubation of the antibody with the 
peptide.  
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Figure 6: Western Blot analysis with mouse tissue extracts 
To find out more about the protein expression in different mouse tissues Western Blot analysis with the anti-
SPARCL1/SC1 antibody was performed. Lu=lung, Li=liver, He=heart, Ki=kidney, Co=cortex, Ce=cerebellum, 
and SmI=small intestine. Equal amounts were loaded except for small intestine where only half of the amount was 
loaded. 
 
 
 
In 15.5 days old mice we found staining in muscle, lung, heart, liver, gastric mucosa, 
and skin, whereas in head sections of 17.5 days old mouse the vibrissae, the cornea, 
and the retina were stained. These results are in accordance to the staining of lung in 
16 days old mice and of surrounding connective tissue of vibrissae in 18 days old 
mice found by in situ hybridization (Soderling et al., 1997). Immunohistochemical 
stainings of the vibrissae could be blocked by preincubation of the antibody with the 
peptide (see figure 7 A+B). Performing immunohistochemistry on mouse paraffin 
sections with the anti-SPARCL1/SC1 antibody we could show that the pattern in adult 
brain (dentate gyrus, pyramidal cells, astrocytes, and purkinje layer) is in accordance 
to published data: Mendis et al. found the same pattern using immunohistochemistry 
and in situ hybridization (Mendis et al., 1996a; Mendis et al., 1994; Mendis et al., 
1996b).  
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Additionally we found staining of the basal lamina of the lung bronchioles (see figure 
7 C), the muscle in different tissues (7 D), and the blood vessels in heart (7 E). 
These results are in accordance to the staining of lung bronchioles and heart blood 
vessels found by in situ hybridization (Soderling et al., 1997). SC1 mRNA expression 
in muscle was so far only proven by Northern Blot analysis (McKinnon et al., 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Selection of immunohistochemistry stainings on mouse paraffin sections 
Immunohistochemistry on mouse paraffin sections was performed to confirm the specificity of the anti-
SPARCL1/SC1 antibody. A: vibrissae staining of a 17.5 days old mouse embryo. B: vibrissae staining was 
blocked when the antibody was preincubated with the corresponding peptide. C: staining of the basal lamina of a 
bronchiole (adult mouse lung). D: muscular staining in adult mouse colon (marked with →). E: staining of a blood 
vessel (marked with ∗) in adult mouse heart. Counterstaining of the nuclei was performed using haematoxylin 
(blue). A, B, D, and E: bar 50 µm & C: bar 500 µm 
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SPARCL1 expression in human tissue 
As SPARCL1 was found to be downregulated on mRNA and protein level in human 
NSCLCs and as its transcript is also downregulated in human colon carcinomas 
(Claeskens et al., 2000; Notterman et al., 2001) a role of SPARCL1 in colon cancer 
was expected. Therefore, we wanted to investigate the SPARCL1 protein expression 
pattern particularly in colon cancer. Additionally, investigation of SPARCL1 
expression in colon adenoma could give insight whether the downregulation of 
SPARCL1 takes place in early stages of cancer development.  
Immunohistochemistry on human tissue sections was not trivial and we could not 
directly adapt the mouse protocol for humans. Therefore, we tried to optimize the 
protocol using many different conditions and antigen retrievals such as citrate buffer 
heated in a microwave and 0.3% Triton followed by 0.75% glycine at room 
temperature. Finally we obtained specific staining patterns with the Discovery system 
(Ventana), whereas results obtained by conventional (“self-made”) procedures were 
difficult to reproduce and often showed a patchy staining. The advantages of the 
Discovery system are: non-solvent based removal of paraffin, automated epitope 
unmasking, flexible primary antibody incubation options, flexible detection options, 
four available detection chemistries, and automated counterstaining. With this system 
we found a staining in colon muscle and blood vessels, whereas epithelium was not 
stained (see figure 8).  
 
 
 
 
 
 
 
 
 
 
Figure 8: Immunohistochemistry on human paraffin sections 
Using the Immunostainer (Ventana) we performed immunohistochemistry with the anti-SPARCL1/SC1 antibody 
on sections of human colon. The muscular staining showed here was found after an additional antigen retrieval 
step. Counterstaining of the nuclei was performed using haematoxylin (blue).  
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 The staining of muscle but not epithelium was unexpected, however, our data could 
be confirmed by Western Blot analysis with human colon tissue extracts with 
carefully separated epithelium and muscle. On the blot we detected no signal in 
epithelium but two bands with a molecular weight of more than 190 kD in muscle 
(see figure 9). Both bands could be blocked by preincubation of the antibody with the 
SPARCL1/SC1 peptide and therefore seem to be specific. 
 
 
 
Figure 9: Western Blot analysis with human colon extracts 
To define the protein expression pattern in human colon Western Blot analysis with the anti-SPARCL1/SC1
antibody was performed. E=epithelium and M=muscle.  
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Discussion 
 
SPARCL1 is downregulated in human NSCLCs and expressed in similar tissue as 
SC1 (Bendik et al., 1998). Therefore, we wanted to know whether SPARCL1 
downregulation is limited to human tumors or whether it also occurs in murine lung 
tumors. 
The A/J mouse model is a good model for lung tumors as it has a high incidence of 
spontaneous tumors and tumors can be induced by carcinogen exposure (for example 
NNK). The lesions have a similar histology as human lung adenomas and evolve over 
a distinct progression from hyperplasia, to benign appearing adenomas, and then to 
frank carcinomas (Vogelstein and Kinzler, 1998). The major determinant of lung 
cancer predisposition in the A/J mouse strain was found to be the Pas1 locus 
(pulmonary adenoma susceptibility) (Manenti et al., 1997). Interestingly, the K-ras2 
proto-oncogene, is located nearby this locus and has been studied in detail: this gene 
is mutated in 70 to over 90% of spontaneous and carcinogen-induced murine lung 
adenocarcinomas and is also mutated in a significant percentage of human lung 
adenocarcinoma (Vogelstein and Kinzler, 1998).  
We had the opportunity to obtain lung tissue sections from A/J mice, which were 
treated with NNK to induce lung tumors. In our study we used a SC1 specific 
riboprobe to perform in situ hybridization on these sections. We found SC1 mRNA 
expression in normal mouse lung whereas it was absent in lung tumors. As SPARCL1 
downregulation in lung tumors is conserved between human and mouse we suggest 
that SPARCL1 downregulation is, at least in lung tumors, an important step in tumor 
formation. 
SPARCL1 is not only downregulated in lung tumors but also in colon (Claeskens et 
al., 2000; Notterman et al., 2001), bladder (Dr. P. Schraml, personal communication), 
and prostate tumors (Nelson et al., 1998). Colon cancer is of big importance as it is a 
very common cancer and as it can be detected at early stages. Additionally it is the 
cancer with the best known order of gene alterations leading to tumor formation. 
Using oligonucleotide arrays Notterman et al. found that SPARCL1 downregulation is 
an early event during colon cancer formation (Notterman et al., 2001). 
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This result is in accordance to unpublished data from our lab. By real-time 
quantitative PCR we found reduced SPARCL1 mRNA expression in colon adenomas 
(compared to normal tissue) in 10 out of 13 patients. However, in colon 
adenocarcinoma the result were not as clear (25% upregulated and 54% 
downregulated). To confirm this downregulation on the protein level and to learn 
more about the protein expression pattern in normal and tumor tissue we decided to 
produce a new polyclonal antibody against a SPARCL1/SC1 peptide in rabbits. This 
antibody was shown to detect specifically a human SPARCL1 construct by Western 
Blot analysis of transfected cell extracts and by immunofluorescence on transfected 
cells. Additionally, we showed that this antibody crossreacts with SC1 protein in 
Western Blot analysis of mouse tissue extracts and in immunohistochemistry on 
mouse paraffin sections. 
Several attempts were needed to get positive immunohistochemistry staining on 
human paraffin sections. As we got patchy staining using conventional procedures we 
changed to the automated Discovery system (Ventana). To our surprise we could not 
detect any SPARCL1 protein in the normal colon epithelium (which is the origin of 
colon cancer), but it was present in the surrounding muscle. This was confirmed by 
Western Blot analysis of carefully separated human epithelium and muscle extracts. 
These data are in disagreement with the published data where SPARCL1 mRNA was 
detected in normal tissue. With our approach we show that SPARCL1 protein is not 
expressed in colon epithelium, but we cannot exclude that SPARCL1 mRNA is 
present and not translated. However, we have strong evidence that the mRNA 
detected in normal colon tissue extracts originates from muscle cells and not from 
epithelial cells. In summary, our results emphasize the necessity to confirm all mRNA 
data on protein level. 
The predicted SPARCL1 monomer has a molecular weight of 75 kD, however, by 
Western Blot analysis of SPARCL1 in human colon we revealed two extraordinary 
high molecular weight SPARCL1 protein bands (>190 kD). These signals seem to be 
specific as we were able to block the reaction by preincubation of the antibody with 
the SPARCL1/SC1 peptide. 
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Interestingly, different molecular weights are published for SPARCL1: Claeskens et 
al. and Bendik et al. found two bands of 75 and 150 kD (Bendik et al., 1998; 
Claeskens et al., 2000), whereas Girard and Baekkevold only found one band (130, 
respectively 110 kD) (Baekkevold et al., 1999; Girard and Springer, 1996). Bendik et 
al. used lung extracts for Western Blot analysis. All the others were expressing the 
SPARCL1 protein in cells. Also for SC1 the published molecular weights differ a lot: 
Johnston et al. found two bands of 116 and 120 kD in brain extracts (Johnston et al., 
1990), whereas Hambrock et al. found a single band of 94 kD when the protein was 
expressed by transfected cells, but two bands of 55 and 116 kD in tissue extracts 
(Hambrock et al., 2003). We found a single SC1 band of 70 kD in different tissue 
extracts. 
The extraordinary high molecular weight of SPARCL1 in colon could be explained by 
strong covalent dimerization other than disulfide bridges (or even higher 
oligomerization), by N-glycosylations (high mannose and/or complex type), by O-
glycosylations, and/or by anomalous electrophoretic behaviour due to atypical binding 
of SDS to the highly negative charged N-terminal domain. To clarify the proportion 
of N-glycosylations in the SPARCL1 protein, it would be necessary to digest the 
protein with endoglycosidase H or N-glycosidase F. 
The putative function of SPARCL1/SC1 is still a matter of speculations. Purified 
SPARCL1/hevin inhibited adhesion of endothelial cells to a fibronectin substrate, 
indicating that SPARCL1 belongs to the family of adhesion modulating proteins, 
which includes SPARC, thrombospondin, and tenascins (Sage and Bornstein, 1991). 
These proteins are structurally unrelated modular glycoproteins. However, all of them 
antagonize the pro-adhesive activities of other matrix proteins, e.g. fibronectin, and 
are thought to regulate the ability of a cell to differentiate, migrate, or proliferate 
(Murphy-Ullrich, 2001). Soderling et al. investigated SC1 mRNA expression by in 
situ hybridization. In organs with SC1 expression, high levels of mRNA were found 
in cells that provide structural support, i.e., smooth muscle cells or fibroblasts 
(Soderling et al., 1997). However, cultured proliferating smooth muscle cells or 
fibroblasts had no detectable SC1 mRNA. Furthermore, it was shown that SPARCL1 
could act as a negative regulator of cell proliferation in HeLa 3S cells (Claeskens et 
al., 2000). These data let us speculate that the main function of SPARCL1/SC1 may 
be to support cellular differentiation rather than promoting proliferation. 
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We hypothesize that SPARCL1 might interfere with cell adhesion and thereby might 
activate a signal that specifically leads to cell cycle arrest or apoptosis if it is 
expressed in inappropriate tissues (e.g. lung cancer). 
It would be interesting to investigate the effects of purified SPARCL1 on cell 
adhesion and cell survival in different cell lines (including cancer cell lines) and to 
investigate the mechanism involved in the regulation of cell proliferation by 
SPARCL1.    
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Abbreviations 
 
aa  aminoacid 
ADC  adenocarcinoma 
Ci  Curie 
ELISA  Enzyme-Linked Immuno Sorbent Assay 
ER  endoplasmatic reticulum 
EST  expressed sequence tag 
FCS  fetal calf serum  
H+E  haemalaun + eosin staining 
HEK  human embryonic kidney 
kb  kilobasepairs  
LB  Luria-Bertani medium 
LCC  large cell carcinoma  
LOH  loss of heterozygosity  
NNK  4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone 
nr  number 
NSCLC non-small cell lung cancer  
nt  nucleotide 
PAGE  polyacrylamide gel electrophoresis 
SCC  squamous cell carcinoma  
SPARC secreted protein acidic and rich in cysteine 
SPARCL1 SPARC-like 1 
TK  thymidine kinase 
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